Evidence map›Paper›PMID 34057181›Full record

ReviewFEMS microbiology letters2021

Synthetic biology approaches to actinomycete strain improvement.

Rainer Breitling, Martina Avbelj, Oksana Bilyk, Francesco Del Carratore, Alessandro Filisetti, Erik K R Hanko, Marianna Iorio, Rosario Pérez Redondo, Fernando Reyes, Michelle Rudden and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in FEMS microbiology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rainer BreitlingDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Martina AvbeljBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia.
Oksana BilykDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Francesco Del CarratoreDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Alessandro FilisettiExplora Biotech Srl, Doulix business unit, Via Torino 107, 30133 Venice, Italy.
Erik K R HankoDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Marianna IorioNaicons srl., Viale Ortles 22/4, 20139 Milano, Italy.
Rosario Pérez RedondoINBIOTEC Instituto de Biotecnología de León, Avenida Real 1, 24006 León, Spain.
Fernando ReyesFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avenida del Conocimiento 34, Parque Tecnologico de Ciencias de la Salud, 18016 Armilla, Granada, Spain.
Michelle RuddenDepartment of Biology, University of York, Wentworth Way, York, YO10 5DD, UK.
Emmanuele SeveriDepartment of Biology, University of York, Wentworth Way, York, YO10 5DD, UK.
Lucija SlemcBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia.
Kamila SchmidtDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Dominic R WhittallDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Stefano DonadioNaicons srl., Viale Ortles 22/4, 20139 Milano, Italy.
Antonio Rodríguez GarcíaINBIOTEC Instituto de Biotecnología de León, Avenida Real 1, 24006 León, Spain.
Olga GenilloudFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avenida del Conocimiento 34, Parque Tecnologico de Ciencias de la Salud, 18016 Armilla, Granada, Spain.
Gregor KosecAcies Bio d.o.o., Tehnološki Park 21, 1000, Ljubljana, Slovenia.
Davide De LucreziaExplora Biotech Srl, Doulix business unit, Via Torino 107, 30133 Venice, Italy.
Hrvoje PetkovićBiotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia.
Gavin ThomasDepartment of Biology, University of York, Wentworth Way, York, YO10 5DD, UK.
Eriko TakanoDepartment of Chemistry, Manchester Institute of Biotechnology, Manchester Synthetic Biology Research Centre SYNBIOCHEM, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

Funding

Biotechnology and Biological Sciences Research Council BB/M017702/1
6 · The paper itself

Abstract

Their biochemical versatility and biotechnological importance make actinomycete bacteria attractive targets for ambitious genetic engineering using the toolkit of synthetic biology. But their complex biology also poses unique challenges. This mini review discusses some of the recent advances in synthetic biology approaches from an actinomycete perspective and presents examples of their application to the rational improvement of industrially relevant strains.

Indexed as

ActinobacteriaIndustrial MicrobiologyMetabolic EngineeringSynthetic Biologyactinobacteriaactinomycetebiosynthesisbiotechnologysynthetic biology

Identifiers

PMID34057181
PMCPMC8195692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.